TY - JOUR
T1 - N-Terminal Pro-Brain Type Natriuretic Peptide Predicts Cardiovascular Events Independently of Arterial Stiffness, Assessed By Carotid-to-Femoral Pulse Wave Velocity, in Apparently Healthy Subjects
AU - Frary, Charles Edward
AU - Blicher, Marie Kofoed
AU - Olesen, Thomas Bastholm
AU - Pareek, Manan
AU - Vishram-Nielsen, Julie K.K.
AU - Rasmussen, Susanne
AU - Olsen, Michael Hecht
N1 - Publisher Copyright:
© 2023 The Authors
PY - 2024/3
Y1 - 2024/3
N2 - Aim: This study aimed to evaluate whether N-terminal pro-brain natriuretic peptide (NT-proBNP) and carotid-to-femoral pulse wave velocity (PWV) carried independent prognostic value in predicting cardiovascular events in apparently healthy individuals beyond traditional risk factors. Methods: A total of 1,872 participants aged 41, 51, 61, or 71 years from the MONItoring of trends and determinants in CArdiovascular disease (MONICA) study were included. Traditional risk factors were assessed, including: smoking status; mean systolic and diastolic blood pressure; body mass index; fasting plasma glucose; serum triglycerides; total, high-density, and low-density lipoprotein cholesterol; NT-proBNP; and PWV. The principal endpoint that was assessed during 16 years of follow-up was a composite of major adverse cardiovascular events (MACE). The secondary endpoints were cardiovascular mortality (CVM), hospitalisation for coronary artery disease (CAD), and a composite of hospitalisation for heart failure (HF) or atrial fibrillation (AF). Results: At baseline, NT-proBNP was associated with PWV (β=0.14; p<0.001), but not after adjustment for traditional risk factors (β=–0.01; p=0.67). In models including traditional risk factors and PWV, NT-proBNP was associated with all four outcomes (HRMACE=1.33, 95% CI 1.16–1.52; HRCVM=2.02, 95% CI 1.65–2.48; HRCAD=1.29, 95% CI 1.07–1.55; and HRHF or AF=1.79, 95% CI 1.40–2.28). In the same model, PWV was only associated with CVM (HRCVM=1.20, 95% CI 1.01–1.41). No interactions between NT-proBNP and PWV were found. N-terminal pro-brain natriuretic peptide significantly improved net reclassification (NRI) for MACE (NRI=0.12; p=0.03), CVM (NRI=0.33; p<0.001), and HF or AF (NRI=0.33; p<0.001) beyond traditional risk factors, while PWV did not aid in net reclassification improvement for any endpoint. Conclusions: In apparently healthy individuals, NT-proBNP and PWV predicted cardiovascular events independently. N-terminal pro-brain natriuretic peptide improved reclassification for the prediction of MACE, CVM, and hospitalisation for HF or AF beyond traditional risk factors, while PWV did not.
AB - Aim: This study aimed to evaluate whether N-terminal pro-brain natriuretic peptide (NT-proBNP) and carotid-to-femoral pulse wave velocity (PWV) carried independent prognostic value in predicting cardiovascular events in apparently healthy individuals beyond traditional risk factors. Methods: A total of 1,872 participants aged 41, 51, 61, or 71 years from the MONItoring of trends and determinants in CArdiovascular disease (MONICA) study were included. Traditional risk factors were assessed, including: smoking status; mean systolic and diastolic blood pressure; body mass index; fasting plasma glucose; serum triglycerides; total, high-density, and low-density lipoprotein cholesterol; NT-proBNP; and PWV. The principal endpoint that was assessed during 16 years of follow-up was a composite of major adverse cardiovascular events (MACE). The secondary endpoints were cardiovascular mortality (CVM), hospitalisation for coronary artery disease (CAD), and a composite of hospitalisation for heart failure (HF) or atrial fibrillation (AF). Results: At baseline, NT-proBNP was associated with PWV (β=0.14; p<0.001), but not after adjustment for traditional risk factors (β=–0.01; p=0.67). In models including traditional risk factors and PWV, NT-proBNP was associated with all four outcomes (HRMACE=1.33, 95% CI 1.16–1.52; HRCVM=2.02, 95% CI 1.65–2.48; HRCAD=1.29, 95% CI 1.07–1.55; and HRHF or AF=1.79, 95% CI 1.40–2.28). In the same model, PWV was only associated with CVM (HRCVM=1.20, 95% CI 1.01–1.41). No interactions between NT-proBNP and PWV were found. N-terminal pro-brain natriuretic peptide significantly improved net reclassification (NRI) for MACE (NRI=0.12; p=0.03), CVM (NRI=0.33; p<0.001), and HF or AF (NRI=0.33; p<0.001) beyond traditional risk factors, while PWV did not aid in net reclassification improvement for any endpoint. Conclusions: In apparently healthy individuals, NT-proBNP and PWV predicted cardiovascular events independently. N-terminal pro-brain natriuretic peptide improved reclassification for the prediction of MACE, CVM, and hospitalisation for HF or AF beyond traditional risk factors, while PWV did not.
KW - Arterial stiffness
KW - Cardiovascular disease
KW - Carotid-to-femoral pulse wave velocity
KW - N-terminal pro-brain type natriuretic peptide
KW - Prognosis
KW - Risk
KW - Brain
KW - Peptide Fragments
KW - Pulse Wave Analysis
KW - Humans
KW - Risk Factors
KW - Healthy Volunteers
KW - Natriuretic Peptide, Brain
KW - Biomarkers
KW - Heart Failure
KW - Vascular Stiffness
KW - Atrial Fibrillation
U2 - 10.1016/j.hlc.2023.11.015
DO - 10.1016/j.hlc.2023.11.015
M3 - Journal article
C2 - 38290952
AN - SCOPUS:85184266241
SN - 1443-9506
VL - 33
SP - 392
EP - 400
JO - Heart, Lung and Circulation
JF - Heart, Lung and Circulation
IS - 3
ER -